Cashing out in biotech in 2022: On-target predictions for AbbVie, Vertex and Genmab
Panuwat Dangsungnoen/iStock via Getty Images Seeking Contributors urged investors to buy AbbVie (NYSE:ABBV), Vertex Pharma (NASDAQ:VRTX), Genmab (GMAB) and a range of other biotechs in 2022 long before those stocks outperformed − sometimes even as the consensus view on Wall...